Skip to content
  • About
    • Company History
    • Management
    • Board of Directors
    • Collaborators
    • Scientific Advisors
    • Careers
  • Pipeline
    • Platform Technologies Overview
    • Clinical Status
    • Armored CAR-CIK
    • CAR-CIK
    • CAR-CIK Solid Tumors
    • CMN-001 Overview
    • CMN-001 Rationale
    • Publications
  • News
  • Contact
Menu
  • About
    • Company History
    • Management
    • Board of Directors
    • Collaborators
    • Scientific Advisors
    • Careers
  • Pipeline
    • Platform Technologies Overview
    • Clinical Status
    • Armored CAR-CIK
    • CAR-CIK
    • CAR-CIK Solid Tumors
    • CMN-001 Overview
    • CMN-001 Rationale
    • Publications
  • News
  • Contact
Search

CoImmune, Inc. to Participate in Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

DURHAM, NC, September 20, 2021 (PRNEWSWIRE) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced
that Charles Nicolette, chief executive officer of CoImmune, will present a corporate update on September 23, 2021 at 9:05AM EDT during the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. Dr. Nicolette will review progress in development of the company’s allogeneic CAR-CIK technology platform for the treatment of liquid and solid tumors and will be available to participate in one-on-one meetings with investors during the conference being held September 21-23, 2021.

The following link can be accessed on September 23, 2021 at 9:05 AM EDT to watch the presentation live:
https://wsw.com/webcast/oppenheimer16/clmm/2767483

A webcast of the presentation will also be available on the News page of the CoImmune website at https://www.coimmune.com/news/.

About CoImmune, Inc.
CoImmune is a privately held, clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a variation on CAR-T therapy that promises enhanced efficacy with greatly reduced toxicity. Our autologous RNA-loaded dendritic cell technology for solid tumors uses amplified total tumor mRNA to program highly engineered dendritic cells to generate immune responses against neoantigens without the need to identify them.

###

Investor Contact:
Lori Harrelson
Chief Financial Officer
CoImmune, Inc.
lharrelson@coimmune.com

Media Contact:
Adam Daley
Berry & Company Public Relations
bberry@berrypr.com
212-253-8881

Post navigation
← Previous Press Release
Next Press Release →
coimmune-text-only-r
4233 Technology Drive | Durham NC 27704 | 919-287-6300
Linkedin-in Twitter
©2023 cōIMMUNE® | All rights reserved